Emcure’s Initiatives in Anemia Management Dr. P. Bhandari, M.D.

We bring difference in lives Emcure Research driven pharmaceutical company Responsible corporate citizen giving back to society from which it profits Therapeutic areas Anemia AIDS Cardiology Nephrology Oncology Gynecology Diabetes Neurology Orthopedics Gastroenterology We bring difference in lives

Anemia – a global problem According to a survey conducted by NFHS, the prevalence of anaemia in young girls aged between 15-24 years is 56% with higher rates in rural than in urban India.

Anemia affects all Mother Child Pre-term delivery Fetal and maternal mortality Low birth weigh baby Child Impaired mental function Increased infections Frequent diarrhea

Anemia – signs/symptoms Fatigue (very common) Weakness (very common) Dizziness Shortness of breath Irritability Lack of concentration Pale skin and tongue Brittle nails Low hemoglobin Iron deficiency anaemia with depapillated tongue, depigmentation of the upper lip and epithelial erosion of the lower lip

Emcure in Anaemia management Innovative oral iron products: Ferrous ascorbate tablets, suspension, etc. State of the art parenteral iron products: Iron sucrose injection Ferric carboxymaltose injection Biotechnology products: Erythropoietin

Ferrous Ascorbate Leaders in the ferrous ascorbate market Offering own R&D ferrous ascorbate Granted Indian Patent The best oral iron so far: Maximum bioavailability of up to 43% Excellent tolerability Prevents inhibitory action of dietary phytates etc Proven safety and efficacy Dose: 100 mg elemental iron daily for adults

Why Ferrous Ascorbate? Inhibitors Facilitators The absorption of iron from ordinary iron supplements is approximately 10% or less This is due to presence of inhibitory ligands like phytates, tannins, phosphates etc in food The presence of ascorbate facilitates absorption by preventing the action of these inhibitory ligands This increase absorption of iron from ferrous ascorbate up to 43%

When oral iron may not be sufficient? In severe anemia that will require very long time to correct Very low iron stores that need quick replenishment In renal failure patients who do not respond to oral iron In menorrhagia-associated severe iron-deficiency anemia In anemia associated with cancer  Parenteral (IV) iron

Iron Sucrose Injection The dominant IV iron for anaemia management Does not have risk of dextran-induced hypersensitivity Used by both nephrologists and obstetricians Dose: 100 mg by slow IV bolus x max thrice weekly, or 100-200 mg IV infusion x max thrice weekly, to replenish cumulative deficit

Ferric Carboxymaltose Injection The latest IV iron Introduced first in India by Emcure Offers feasibility of total dose infusion of 1g in 15 min No dextran-type hypersensitivity Safe & effective in different indications

Erythropoietin Manufactured in Gennova Biopharmaceuticals facility of Emcure Matching European Pharmacopoeia standards Used by nephrologists in renal anemia Used by obstetricians in EPO-deficient IDA in pregnancy

FOGSI – Emcure Social Responsibility

Emcure’s Corporate Social Responsibility

Emcure’s Corporate Social Responsibility

Emcure’s Corporate Social Responsibility

Emcure’s Corporate Social Responsibility

FOGSI-Emcure Publications http://haemoglobin-anaemia.com/fogsipublication.asp

Emcure in Anemia Management Latest research and development Quality products Education, awareness and support through CSR activities We bring difference in lives

Emcure’s websites www.emcure.co.in http://haemoglobin-anaemia.com